Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Nov 3, 2025, 9:30 AM EST
Seelos Therapeutics Revenue
Seelos Therapeutics had revenue of $376.00K in the quarter ending June 30, 2024, with 11.90% growth. This brings the company's revenue in the last twelve months to $2.01M, up 76.05% year-over-year. In the year 2023, Seelos Therapeutics had annual revenue of $2.20M.
Revenue (ttm)
2.01M
Revenue Growth
+76.05%
P/S Ratio
0.00
Revenue / Employee
251.75K
Employees
16
Market Cap
136.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.20M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 375.00K | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Seelos Therapeutics News
- 1 year ago - Seelos Announces Second Postponement of its Annual Meeting of Stockholders - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - PRNewsWire
- 1 year ago - Seelos Announces Postponement of its Annual Meeting of Stockholders - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces 1-for-16 Reverse Stock Split - PRNewsWire
- 1 year ago - Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - PRNewsWire
- 1 year ago - Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations - PRNewsWire